| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FIBP |
| Uniprot No | O43427 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-364aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMTSELDIFVGNTTLIDEDVYRLWLDGY SVTDAVALRVRSGILEQTGATAAVLQSDTMDHYRTFHMLERLLHAPPKLL HQLIFQIPPSRQALLIERYYAFDEAFVREVLGKKLSKGTKKDLDDISTKT GITLKSCRRQFDNFKRVFKVVEEMRGSLVDNIQQHFLLSDRLARDYAAIV FFANNRFETGKKKLQYLSFGDFAFCAELMIQNWTLGAVGEAPTDPDSQMD DMDMDLDKEFLQDLKELKVLVADKDLLDLHKSLVCTALRGKLGVFSEMEA NFKNLSRGLVNVAAKLTHNKDVRDLFVDLVEKFVEPCRSDHWPLSDVRFF LNQYSASVHSLDGFRHQALWDRYMGTLRGCLLRLYHD |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FIBP(FGF细胞内结合蛋白)重组蛋白研究的3篇文献示例，内容基于公开研究整理：
---
1. **文献名称**：*"Cloning, expression, and functional analysis of FIBP in modulating FGF signaling pathways"*
**作者**：Zhang L, et al.
**摘要**：研究报道了人源FIBP基因的克隆及其在大肠杆菌中的重组表达，发现纯化的重组FIBP蛋白可抑制FGF2介导的细胞增殖，提示其在调控FGF信号通路中的潜在作用。
2. **文献名称**：*"Structural characterization of recombinant FIBP and its interaction with FGF1"*
**作者**：Kim S, Park JH.
**摘要**：通过X射线晶体学解析了重组FIBP蛋白的三维结构，并利用表面等离子体共振技术证实FIBP与FGF1的直接结合，阐明了其结合域的关键氨基酸残基。
3. **文献名称**：*"FIBP knockdown enhances chemosensitivity in cancer cells via regulating mitochondrial apoptosis"*
**作者**：Wang Y, et al.
**摘要**：研究发现，通过siRNA沉默FIBP基因或使用重组FIBP拮抗剂处理，可显著增强肿瘤细胞对化疗药物的敏感性，机制与线粒体凋亡通路激活相关。
---
注：以上文献为示例性内容，实际引用需以真实发表的论文为准。建议通过PubMed或Web of Science以“FIBP recombinant protein”、“FGF intracellular-binding protein”等关键词检索最新研究。
**Background of FIBP Recombinant Protein**
Fibroblast growth factor (FGF)-interacting protein (FIBP) is an intracellular protein that interacts with fibroblast growth factors (FGFs), a family of signaling proteins involved in diverse biological processes, including cell proliferation, differentiation, angiogenesis, and tissue repair. FIBP was initially identified as a cytoplasmic binding partner of FGF-1 and FGF-2. playing a regulatory role in their intracellular trafficking and signaling. Structurally, FIBP contains a conserved FGF-binding domain and is implicated in modulating FGF-mediated pathways by influencing their stability, subcellular localization, or interaction with receptors.
Recombinant FIBP refers to the protein produced through genetic engineering techniques, typically expressed in bacterial or mammalian systems. This approach allows large-scale production of highly pure, biologically active FIBP for research and therapeutic applications. The recombinant form retains the functional properties of native FIBP, enabling studies on its role in FGF signaling, cancer biology (e.g., tumor growth and metastasis), and developmental processes.
Interest in FIBP has grown due to its potential as a therapeutic target. Dysregulation of FGF signaling is linked to cancers, metabolic disorders, and fibrotic diseases, positioning FIBP as a modulator of pathological pathways. Additionally, recombinant FIBP serves as a tool to investigate FGF-dependent mechanisms in vitro and in vivo, aiding drug discovery and molecular diagnostics. Its production via recombinant technology ensures consistency, scalability, and customization (e.g., tagged versions for detection), making it valuable for both basic research and clinical applications. Further studies aim to clarify its precise molecular interactions and therapeutic potential.
×
